Business Context and Reporting Period
Date: February 13, 2017
Company: Miragen Therapeutics, Inc. (formerly Signal Genetics, Inc.)
Event: Completion of a business combination (reverse merger) with Private Miragen Therapeutics, Inc. and a concurrent disposition of assets.
Following the merger, the Registrant changed its name to Miragen Therapeutics, Inc. and its ticker symbol from "SGNL" to "MGEN" on the NASDAQ Capital Market. The company's primary business is now the clinical-stage biopharmaceutical operations of Private Miragen, focusing on RNA-targeted therapeutics and microRNAs.
Key Financial Metrics and Transactions
- Asset Disposition Proceeds: The company sold its MyPRS intellectual property assets to Quest Diagnostics Investments LLC for a total consideration of approximately $946,431 ($825,000 base + $100,000 lab operation fee + $21,431 reimbursement).
- Debt Obligations: The Registrant assumed a loan agreement with Silicon Valley Bank for up to $10 million.
- Tranche 1: $5.0 million funded (May 2015), repayable over 48 months with interest-only payments for the first 18 months.
- Tranche 2: $5.0 million available upon achievement of specified clinical milestones (mechanistic proof-of-concept for MRG-106 Phase 1).
- Interest Rate: Prime rate minus 0.25% (3.50% as of Dec 31, 2016).
- Final Payment Fee: 5.50% of amounts borrowed.
- Capital Structure: Immediately post-merger, there were approximately 21.3 million shares of common stock outstanding. Former Private Miragen stockholders own approximately 96% of the fully-diluted common stock.
- Recent Financing: Immediately prior to the merger, Private Miragen raised approximately $40.7 million in a private placement at $4.50 per share.
Material Changes Versus Prior Period
- Corporate Identity: The company changed its name from Signal Genetics, Inc. to Miragen Therapeutics, Inc. and its ticker symbol from SGNL to MGEN.
- Business Focus: The company shifted from its previous operations to the clinical-stage biopharmaceutical business of Private Miragen.
- Asset Base: The company divested its MyPRS test intellectual property assets, retaining only accounts receivable as of the transaction date.
- Ownership: Control shifted significantly; former Signal Genetics shareholders now hold approximately 4% of the fully-diluted equity, while former Private Miragen shareholders hold approximately 96%.
- Accounting Firm: The company dismissed BDO USA, LLP and engaged KPMG LLP as its principal accountants for the fiscal year ending December 31, 2017.
Management Commentary, Risks, and Unusual Items
- Management Changes: The entire board of directors and executive officers were replaced.
- CEO: William S. Marshall, Ph.D. (Base salary: $400,000; Bonus target: 50%).
- CFO: Jason A. Leverone (Base salary: $280,000; Bonus target: 35%).
- CBO: Adam S. Levy (Base salary: $300,000; Bonus target: 40%).
- EVP R&D: Paul D. Rubin, M.D. (Base salary: $395,000; Bonus target: 40%).
- Severance Provisions: New executive agreements include significant severance packages (12 months salary + equity vesting) for termination without cause or resignation for good reason, increasing to 24 months salary for the CEO in the event of a change of control.
- Debt Covenants: The second tranche of the $10 million loan is contingent on achieving mechanistic proof-of-concept for the MRG-106 Phase 1 clinical trial. Failure to meet milestones could impact liquidity.
- Related Party Transactions: Significant portions of the pre-merger financing ($40.7M) and Series C convertible preferred stock ($41.1M) were purchased by entities affiliated with new board members (Atlas Venture, Boulder Ventures, Remeditex Ventures).
Investor Verification Checklist
- Verify the pro forma financial information filed as Exhibit 99.2 to understand the combined financial position post-merger.
- Confirm the status of the MRG-106 Phase 1 clinical trial, as it is a condition precedent for accessing the remaining $5 million tranche of the Silicon Valley Bank loan.
- Review the employment agreements (Exhibits 10.3 through 10.6) to assess the total potential cash and equity compensation obligations to new executives.
- Examine the related party transactions regarding the $40.7 million private placement and Series C stock purchases to understand the concentration of ownership among new directors and their affiliates.
- Monitor the transition of the MyPRS asset sale to Quest Diagnostics to ensure no retained liabilities or disputes arise from the assigned contracts.